alpha-MSH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
== History == The practice originated within online incel and manosphere communities during the 2010s, where discussions attributed sexual success to the perceived genetic advantages held by certain men, calling them "Chads". The three main forums in which looksmaxxing originated from, concomitant with the black pill ideology, were the websites PUAHate.com, Sluthate.com, and Lookism.net (called the "PSL Forums", taken from their names). This overarching online community came to be known as the "PSL community". Along with their focus on looksmaxxing and black pill ideas, these websites also rejected mainstream dating culture and feminist perspectives. Looksmaxxing was framed as a strategy for social recognition. It especially involved the adaptation to the perceived dominant male beauty standards, as a means to attract women. These forums established their own measuring unit to rate looks, titled the PSL Scale (standing for "Perceived Sexual Levels", but also an abbreviation for each of the three main forums, in order). The PSL scale diverges from the traditional scale "x out of ten" numerical attractiveness rating system, in that it uses a rigorously hierarchical and systematic framework used to measure only facial attractiveness. It typically uses a scale from 1–8, and it was strictly designed with the aim of interpreting how women perceive men. Many of the terms and jargon associated with looksmaxxing find their origins on these forums.
After the war, Mahathir graduated from secondary school with the highest rank and enrolled to study medicine at the King Edward VII College of Medicine in Singapore. Mahathir studied medicine at what was then called the University of Malaya, later renamed the University of Singapore. When the university granted him an honorary degree in November 2018, he said "I will always value my stay in Singapore for nearly six years." During his college years, Mahathir developed a passion for driving, often travelling long distances, including from Singapore to his hometown in Alor Setar, in his convertible. In 1947, Mahathir, writing under the pen name 'Che Det' in The Sunday Times, published an article titled Malay Women Make Their Own Freedom, in which he discussed the struggle of Malay women in the post-war period and stated, "It is up to the men and especially the fathers, to realise that they can no longer confine their womenfolk to the kitchen."
Colin Pitchfork was arrested in 1987 and it was found that his DNA profile matched the semen samples from the murder. Because of this case, DNA databases were developed. There is the national (FBI) and international databases as well as the European countries (ENFSI: European Network of Forensic Science Institutes). These searchable databases are used to match crime scene DNA profiles to those already in a database.
Sources: en.wikipedia.org
Uranium-235 makes up about 0.72% of natural uranium. Unlike the predominant isotope uranium-238, it is fissile, i.e., it can sustain a fission chain reaction. It is the only fissile isotope that is a primordial nuclide or found in significant quantity in nature. Uranium-235 has a half-life of 704 million years. It was discovered in 1935 by Arthur Jeffrey Dempster. Its fission cross section for slow thermal neutrons is about 584.3±1 barns. For fast neutrons it is on the order of 1 barn. At thermal energy levels, about 5 of 6 neutron absorptions result in fission and 1 of 6 result in neutron capture forming uranium-236. The fission-to-capture ratio improves for faster neutrons.
thermal abuse, e.g. poor cooling or external fire, electrical abuse, e.g. overcharge or external short circuit, mechanical abuse, e.g. penetration or crash, or internal short circuit, e.g. due to manufacturing flaws or aging. Because of these risks, testing standards are more stringent than those for acid-electrolyte batteries, requiring both a broader range of test conditions and additional battery-specific tests, and there are shipping limitations imposed by safety regulators. There have been battery-related recalls by some companies, including the 2016 Samsung Galaxy Note 7 recall for battery fires. Lithium-ion batteries have a flammable liquid electrolyte. A faulty battery can cause a serious fire. Faulty chargers can affect the safety of the battery because they can destroy the battery's protection circuit. While charging at temperatures below 0 °C, the negative electrode of the cells gets plated with pure lithium, which can compromise the safety of the whole pack. Short-circuiting a battery will cause the cell to overheat and possibly to catch fire. Smoke from thermal runaway in a Li-ion battery is both flammable and toxic. Batteries are tested according to the UL 9540A fire standard, and the TS-800 standard also tests fire propagation from one battery container to adjacent containers.
=== Live data === Files that are actively being updated present a challenge to back up. One way to back up live data is to temporarily quiesce them (e.g., close all files), take a "snapshot", and then resume live operations. At this point the snapshot can be backed up through normal methods. A snapshot is an instantaneous function of some filesystems that presents a copy of the filesystem as if it were frozen at a specific point in time, often by a copy-on-write mechanism. Snapshotting a file while it is being changed results in a corrupted file that is unusable. This is also the case across interrelated files, as may be found in a conventional database or in applications such as Microsoft Exchange Server. The term fuzzy backup can be used to describe a backup of live data that looks like it ran correctly, but does not represent the state of the data at a single point in time. Backup options for data files that cannot be or are not quiesced include:
Sources: en.wikipedia.org
==== Innate immunity ==== Cells in the innate immune system use pattern recognition receptors to recognize molecular structures produced by pathogens, identifying two classes of molecules: pathogen-associated molecular patterns (PAMPs), which are associated with microbial pathogens, and damage-associated molecular patterns (DAMPs), which are associated with components of hosts' cells that are released during cell damage or cell death.
==== Reclaimed water as feedstock ==== As semiconductor fabrication has scaled, the volume of feedwater required for ultrapure water production has grown substantially, with advanced fabrication plants consuming several million gallons of UPW per day. To reduce reliance on freshwater withdrawals, some manufacturers have begun using reclaimed municipal or industrial wastewater as raw feedstock for UPW production. Reclaimed water typically contains higher levels of small-molecule organic pollutants such as urea, which are not effectively removed by conventional ion exchange, reverse osmosis, or ultraviolet treatment. As a result, advanced oxidation processes (AOPs), including UV-AOP and sulfate-radical–based methods, have been investigated as supplementary unit operations to meet the increasingly stringent total organic carbon specifications required for sub-7 nm device fabrication.
Witnesses included FDA officials. They looked into several areas: the delay in reporting by Menu Foods, the lack of federal inspections of pet food facilities, and incomplete reporting by the FDA since the start of the recall. During the hearing Senators Durbin and Byrd criticized the government's response during the recall. Durbin specifically criticized the lack of any regular inspection practices or quality control with regards to pet food safety. Senator Kohl criticized the FDA's communication to the public about recalled foods, noting that volunteer websites had more detailed and easier-to-access information about the extent of the problem and which specific foods are of concern than FDA's online resources which Kohl said was contradictory of itself at times, and which the FDA official giving testimony admitted to being difficult to navigate. On 18 April 2007, Senator Durbin and Representative DeLauro met with US FDA Commissioner von Eschenbach to discuss the additional rice protein recalls and learned that the Chinese government was blocking outside attempts to investigate the contamination. In response, they sent a letter to Zhou Wenzong, China's Ambassador to the United States saying in part that "contaminated batches of wheat gluten and rice protein responsible for these events were imported from China" and that "no level of melamine should be found in pet or human food" and asking for visas for inspectors from the United States.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.